{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Tyra+Biosciences%2C+Inc",
    "query": {
      "sponsor": "Tyra Biosciences, Inc"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T20:40:50.937Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06915753",
      "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Hepatocellular Carcinoma",
        "Solid Tumors",
        "Solid Tumor, Adult",
        "FGFR Gene Amplification",
        "FGFR Gene Alterations",
        "Advanced Solid Tumors",
        "FGFR4 Gene Mutation",
        "FGFR4 Gene Fusions",
        "FGF19 Gene Amplification",
        "FGF19 Gene Overexpression",
        "Locally Advanced Unresectable Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "TYRA-430",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2025-04-24",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-11T20:40:50.937Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06915753"
    },
    {
      "nct_id": "NCT05544552",
      "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Solid Tumor",
        "Urothelial Carcinoma",
        "Solid Tumor, Adult",
        "Bladder Cancer",
        "Non-muscle-invasive Bladder Cancer",
        "FGFR3 Gene Mutation",
        "FGFR3 Gene Alteration",
        "Advanced Solid Tumor",
        "Advanced Urothelial Carcinoma",
        "Urinary Tract Cancer",
        "Urinary Tract Tumor",
        "Urinary Tract Carcinoma"
      ],
      "interventions": [
        {
          "name": "TYRA-300",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 310,
      "start_date": "2022-11-22",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-10-11T20:40:50.937Z",
      "location_count": 7,
      "location_summary": "Boston, Massachusetts • Worchester, Massachusetts • New York, New York + 4 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worchester",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05544552"
    },
    {
      "nct_id": "NCT07265947",
      "title": "Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low Grade Upper Tract Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Dabogratinib (TYRA-300) 60mg",
          "type": "DRUG"
        },
        {
          "name": "Dabogratinib (TYRA-300) 80mg",
          "type": "DRUG"
        },
        {
          "name": "Dabogratinib (TYRA-300) TBD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2025-12-22",
      "completion_date": "2030-11",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-11T20:40:50.937Z",
      "location_count": 23,
      "location_summary": "Loma Linda, California • Los Angeles, California • Tampa, Florida + 20 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lisle",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07265947"
    },
    {
      "nct_id": "NCT06160752",
      "title": "Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Cholangiocarcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Solid Tumor",
        "Metastatic Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles",
          "type": "DRUG"
        },
        {
          "name": "Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2023-11-22",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-10-11T20:40:50.937Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06160752"
    },
    {
      "nct_id": "NCT06842355",
      "title": "A Study of TYRA-300 in Children With Achondroplasia: BEACH301",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Achondroplasia"
      ],
      "interventions": [
        {
          "name": "TYRA-300 0.125 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "TYRA-300 0.25 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "TYRA-300 0.375 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "TYRA-300 0.50 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "TYRA-300 0.625 mg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "10 Years",
        "sex": "ALL",
        "summary": "3 Years to 10 Years"
      },
      "enrollment_count": 92,
      "start_date": "2025-03-04",
      "completion_date": "2030-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-11T20:40:50.937Z",
      "location_count": 12,
      "location_summary": "Torrance, California • Aurora, Colorado • Wilmington, Delaware + 9 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06842355"
    },
    {
      "nct_id": "NCT06995677",
      "title": "Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low-grade NMIBC",
        "FGFR Gene Amplification",
        "FGFR Gene Alterations",
        "FGFR3 Gene Alteration",
        "FGFR3 Gene Mutation",
        "FGFR3 Gene Fusions"
      ],
      "interventions": [
        {
          "name": "TYRA-300 60mg",
          "type": "DRUG"
        },
        {
          "name": "TYRA-300 50mg",
          "type": "DRUG"
        },
        {
          "name": "TYRA-300 Dose 70 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2025-06-27",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-11T20:40:50.937Z",
      "location_count": 36,
      "location_summary": "Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 31 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06995677"
    }
  ]
}